Minerva Neurosciences names board member
This article was originally published in Scrip
Waltham, Massachusetts-based Minerva Neurosciences has named Dr Fouzia Laghrissi-Thode to its board of directors. In the past, Dr Laghrissi-Thode has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently vice-president of the cardiovascular and metabolism therapy area at AstraZeneca.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.